Chembio Diagnostics announced the approval of its DPP Zika/Dengue/Chikungunya System by Agencia Nacional de Vigilancia Sanitaria, or ANVISA, Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos/Fiocruz. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous detection of antibodies for both active, or IgM, and prior exposure, or IgG, to the Zika, dengue and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s DPP Micro Reader. An evaluation of the multiplex test by Brazil’s Instituto Nacional de Controle de Qualidade em Saude demonstrated analytical performance using patient samples in this endemic region, with all six results yielding sensitivity between 95.2%-100% and specificity between 96.6%-100%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.